Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hila Haskelberg

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapyHila Haskelberg, Patrick W G Mallon, Jennifer Hoy, et al.
The British Journal of Nutrition|March 18, 2016
High variation in manufacturer-declared serving size of packaged discretionary foods in AustraliaHila Haskelberg, Bruce Neal, Elizabeth Dunford, et al.
The Journal of Infectious Diseases|September 21, 2011
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trialHelen Byakwaga, Mark Kelly, Damian F J Purcell, et al.
Journal of Affective Disorders|September 29, 2018
A randomized controlled trial of 'MUMentum Pregnancy': Internet-delivered cognitive behavioral therapy program for antenatal anxiety and depressionSiobhan A Loughnan, Amanda Sie, Megan J Hobbs, et al.
Trials|April 29, 2026
Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic riskPhyo Pyae Nyein, Hila Haskelberg, Marianne Martinello, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 30, 2014
Bone mineral density over 96 weeks in adults failing first-line therapy randomized to raltegravir/lopinavir/ritonavir compared with standard second-line therapyHila Haskelberg, Patrick W G Mallon, Jennifer Hoy, et al.
The British Journal of Nutrition|March 18, 2016
High variation in manufacturer-declared serving size of packaged discretionary foods in AustraliaHila Haskelberg, Bruce Neal, Elizabeth Dunford, et al.
The Journal of Infectious Diseases|September 21, 2011
Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trialHelen Byakwaga, Mark Kelly, Damian F J Purcell, et al.
Journal of Affective Disorders|September 29, 2018
A randomized controlled trial of 'MUMentum Pregnancy': Internet-delivered cognitive behavioral therapy program for antenatal anxiety and depressionSiobhan A Loughnan, Amanda Sie, Megan J Hobbs, et al.
Trials|April 29, 2026
Optimizing metabolic management on integrase-based ART (OPTIMAR): study protocol for a 2 × 2 factorial, randomised, double-blind placebo-controlled trial to compare the addition of dapagliflozin versus placebo, and rosuvastatin plus ezetimibe versus pitavastatin, in people with HIV on integrase strand transfer inhibitor-based antiretroviral therapy with elevated metabolic riskPhyo Pyae Nyein, Hila Haskelberg, Marianne Martinello, et al.
Pageof 3